Real-world risk of cardiovascular outcomes associated with hypertriglyceridemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies
Lawler PR, Kotrri G, Koh M, Goodman SG, Farkouh ME, Lee DS, Austin PC, Udell JA, Ko DT. Eur Heart J. 2019; Nov 16 [Epub ahead of print]. https://doi.org/10.1093/eurheartj/ehz767
Aims — Hypertriglyceridemia in patients with atherosclerotic cardiovascular disease (ASCVD) has been in focus following the REDUCE-IT trial showing benefit with icosapent ethyl. Among individuals with prevalent ASCVD, we sought to quantify the contemporary, real-world risk of ASCVD events associated with hypertriglyceridemia, as well as estimate icosapent ethyl eligibility and compare trial participants with REDUCE-IT-like individuals in the population.
Methods and Results — We examined data from 2,424,865 adults with lipid panels in the Ontario population. Among those with prevalent ASCVD, we examined adjusted associations between triglyceride (TG) and ASCVD events (first occurrence of myocardial infarction, unstable angina, stroke or transient ischemic attack, coronary revascularization, or cardiovascular death). The proportion of patients with ASCVD potentially eligible for icosapent ethyl was estimated those with TG 135-499 mg/dL (1.52-5.63 mmol/L) and LDLc 41-100 mg/dL (1.06-2.59 mmol/L), similar to the lipid cut-offs in REDUCE-IT, and their demographics and event rates examined. Among 196,717 individuals with ASCVD, median age was 69 years and 30% were female. A total of 24,097 composite ASCVD events occurred over a mean (SD) 2.9 (0.5) years of follow-up. Increasing TG was associated with a graded, progressively higher hazard of ASCVD events. Twenty five percent (49,886) of individuals with ASCVD had hypertriglyceridemia and controlled LDLc; these patients were demographically similar to those in REDUCE-IT with comparable event rates.
Conclusions — Among patients with ASCVD, hypertriglyceridemia is common, and is associated with higher ASCVD risk across a range of TG. It is possible that as many as one in four patients with ASCVD may be candidates for emerging therapies.